NASDAQ:LENZ LENZ Therapeutics (LENZ) Stock Price, News & Analysis $27.93 +0.97 (+3.60%) (As of 11/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About LENZ Therapeutics Stock (NASDAQ:LENZ) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get LENZ Therapeutics alerts:Sign Up Key Stats Today's Range$26.12▼$28.5850-Day Range$20.65▼$28.5052-Week Range$14.07▼$31.00Volume116,734 shsAverage Volume134,567 shsMarket Capitalization$768.08 millionP/E RatioN/ADividend YieldN/APrice Target$35.40Consensus RatingBuy Company OverviewLENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.Read More… The most productive 1 min of your day… (Ad)This next step in your trading career is a simple, yet important one. I want you to take 1 minute to sign up for FREE algo alerts powered by StocksToTrade.>> Click Here To Sign Up For StocksToTrade’s Algo Alerts << LENZ Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks49th Percentile Overall ScoreLENZ MarketRank™: LENZ Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 610th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingLENZ Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLENZ Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about LENZ Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for LENZ Therapeutics are expected to grow in the coming year, from ($3.15) to ($2.85) per share.Price to Book Value per Share RatioLENZ Therapeutics has a P/B Ratio of 1.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about LENZ Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.96% of the float of LENZ Therapeutics has been sold short.Short Interest Ratio / Days to CoverLENZ Therapeutics has a short interest ratio ("days to cover") of 13, which indicates bearish sentiment.Change versus previous monthShort interest in LENZ Therapeutics has recently increased by 3.08%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLENZ Therapeutics does not currently pay a dividend.Dividend GrowthLENZ Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.96% of the float of LENZ Therapeutics has been sold short.Short Interest Ratio / Days to CoverLENZ Therapeutics has a short interest ratio ("days to cover") of 13, which indicates bearish sentiment.Change versus previous monthShort interest in LENZ Therapeutics has recently increased by 3.08%, indicating that investor sentiment is decreasing. News and Social Media3.1 / 5News Sentiment0.58 News SentimentLENZ Therapeutics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for LENZ Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for LENZ on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added LENZ Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, LENZ Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders38.40% of the stock of LENZ Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.32% of the stock of LENZ Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about LENZ Therapeutics' insider trading history. Receive LENZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LENZ Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address LENZ Stock News HeadlinesLeerink Partners Sticks to Its Buy Rating for LENZ Therapeutics (LENZ)October 30 at 2:50 PM | markets.businessinsider.comLENZ reports positive Chinese study data for far-sightedness drugOctober 29, 2024 | msn.comAlgo Trading Is Here 🔥One trade alert each day backed by powerful technology, yours free. For $0 you can get access to one daily stock picked directly from StocksToTrade’s algo-powered system.November 2, 2024 | Timothy Sykes (Ad)LENZ Therapeutics Reports Positive Phase 3 Results For LNZ100 In Presbyopia Trial In ChinaOctober 28, 2024 | markets.businessinsider.comWhy LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving PremarketOctober 28, 2024 | benzinga.comLENZ Therapeutics Shares Climb After Presbyopia Trial Hits EndpointsOctober 28, 2024 | marketwatch.comCORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100October 27, 2024 | globenewswire.comLenz Therapeutics announces FDA acceptance of NDA for LNZ100October 22, 2024 | markets.businessinsider.comSee More Headlines LENZ Stock Analysis - Frequently Asked Questions How have LENZ shares performed this year? LENZ Therapeutics' stock was trading at $16.20 at the beginning of 2024. Since then, LENZ stock has increased by 72.4% and is now trading at $27.93. View the best growth stocks for 2024 here. How were LENZ Therapeutics' earnings last quarter? LENZ Therapeutics, Inc. (NASDAQ:LENZ) issued its earnings results on Wednesday, August, 14th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.09. Who are LENZ Therapeutics' major shareholders? LENZ Therapeutics' top institutional shareholders include SG Americas Securities LLC (0.12%). Insiders that own company stock include Ra Capital Management, LP and James W Mccollum. View institutional ownership trends. How do I buy shares of LENZ Therapeutics? Shares of LENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of LENZ Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that LENZ Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Visa (V), JPMorgan Chase & Co. (JPM) and Netflix (NFLX). Company Calendar Last Earnings8/14/2024Today11/02/2024Next Earnings (Confirmed)11/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:LENZ Previous SymbolNASDAQ:LENZ CUSIPN/A CIK1815776 Webwww.graphitebio.com Phone650-484-0886FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$35.40 High Stock Price Target$38.00 Low Stock Price Target$32.00 Potential Upside/Downside+26.7%Consensus RatingBuy Rating Score (0-4)3.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-124,650,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-57.95% Return on Assets-51.59% Debt Debt-to-Equity RatioN/A Current Ratio23.23 Quick Ratio23.23 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$22.06 per share Price / Book1.27Miscellaneous Outstanding Shares27,500,000Free Float16,938,000Market Cap$768.08 million OptionableN/A Beta0.39 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report This page (NASDAQ:LENZ) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENZ Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENZ Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.